Evaluation of circulating concentrations of CXCL1 (Gro-α), CXCL10 (IP-10) and CXCL12 (SDF-1) in ALL patients prior and post bone marrow transplantation

Pathology Research and Practice

Volumn 208, Issue 10, 2012, Pages 615-619

  Khandany, Behjat Kalantary ^a   Hassanshahi, Gholamhossein ^b   Khorramdelazad, Hossein ^b   Balali, Zohreh ^b   Shamsizadeh, Ali ^b   Arababadi, Mohammad Kazemi ^b   stadebrahimi, Hamid ^b   Fatehi, Abbas ^b   Rezazadeh, Mahboobeh ^b   Ahmadi, Zahra ^b   Karimabad, Mojgan Noroozi ^b  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ALL; BMT; Chemokine; CXCL1 (Gro ); CXCL10 (IP 10) and CXCL12 (SDF 1); Leukemia

Indexed keywords

BIOLOGICAL MARKER; CXCL1 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; STROMAL CELL DERIVED FACTOR 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL STUDY; FEMALE; HUMAN; MALE; MOLECULAR PATHOLOGY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCHOOL CHILD; UPREGULATION;

ADOLESCENT; ANALYSIS OF VARIANCE; BONE MARROW TRANSPLANTATION; CASE-CONTROL STUDIES; CHEMOKINE CXCL1; CHEMOKINE CXCL10; CHEMOKINE CXCL12; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; QUESTIONNAIRES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84867632640     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2012.06.009     Document Type: Article

References (30)

1. Gustafsson G., et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000, 14(12):2267-2275.
2. Smith M.A., Gloeckler-Ries L.A., Gurney J.G., et al. Leukemia: SEER Pediatric Monograph 2005, Bethesda, MD, National Cancer Institute.
3. Singh S., Varney M., Singh R.K. Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res. 2009, 69(2):411-415.
4. Bone-Larson C.L., et al. The role of chemokines in the immunopathology of the liver. Immunol. Rev. 2000, 177:8-20.
5. Tao Y., et al. Bortezomib attenuates acute graft-vs.-host disease through interfering with host immature dendritic cells. Exp. Hematol. 2011, 39(6):710-720.
6. Hassanshahi G., et al. Assessment of NK cells response to hepatocyte derived chemotactic agents. Pak. J. Biol. Sci. 2008, 11(8):1120-1125.
7. Sarris A.H., et al. Human recombinant interferon-inducible protein-10 inhibits the proliferation of normal and acute myelogenous leukemia progenitors. Leukemia 1996, 10(5):757-765.
8. Aiuti A., et al. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J. Exp. Med. 1997, 185(1):111-120.
9. Ponomaryov T., Peled A., Petit I., et al. Increased expression of the chemokine SDF-1 following DNA damage: relevance for human stem cell function. J. Clin. Investig. 2000, 106:1331-1339.
10. Ma Q., Jones D., Springer T.A. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999, 10(4):463-471.
11. Broxmeyer H.E., Cooper H.G.S., Bridger G. Interference of the CXCL12(SDF-1)/CXCR4 axis in mice with AMD3100 induces rapid high level mobilization of hematopoietic progenitor cells, and AMD3100 acts synergistically with G-CSF and MIP-1α to mobilize progenitors. Blood 2001, 98:p810a.
12. Petit I., et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. Nat. Immunol. 2002, 3(7):687-694.
13. Nishii K., et al. Survival of human leukaemic B-cell precursors is supported by stromal cells and cytokines: association with the expression of bcl-2 protein. Br. J. Haematol. 1999, 105(3):701-710.
14. Hassanshahi G., et al. Expression of CXC chemokine IP-10/Mob-1 by primary hepatocytes following heat shock. Saudi Med. J. 2007, 28(4):514-518.
15. Hassanshahi G., et al. Expression of IP-10 chemokine is regulated by pro-inflammatory cytokines in cultured hepatocytes. Iran. J. Allergy Asthma Immunol. 2007, 6(3):115-121.
16. Varley C.L., et al. Regulation of the C-X-C chemokine, mob-1, gene expression in primary rat hepatocytes. Cytokine 2003, 23(3):64-75.
17. Richmond A., Thomas H.G. Melanoma growth stimulatory activity: isolation from human melanoma tumors and characterization of tissue distribution. J. Cell. Biochem. 1988, 36(2):185-198.
18. Wang D., Richmond A. Nuclear factor-kappa B activation by the CXC chemokine melanoma growth-stimulatory activity/growth-regulated protein involves the MEKK1/p38 mitogen-activated protein kinase pathway. J. Biol. Chem. 2001, 276(5):3650-3659.
19. Haskill S., et al. Identification of three related human GRO genes encoding cytokine functions. Proc. Natl. Acad. Sci. U. S. A. 1990, 87(19):7732-7736.
20. Olsnes A.M., et al. T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10) CCL5 (RANTES) and CCL17 (TARC). Cancer Immunol. Immunother. 2006, 55(7):830-840.
21. Griffioen A.W., Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 2000, 52(2):237-268.
22. Foley J.F., et al. Differentiation of human T cells alters their repertoire of G protein alpha-subunits. J. Biol. Chem. 2010, 285(46):35537-35550.
23. Grimm M., et al. Tumor necrosis factor-alpha is associated with positive lymph node status in patients with recurrence of colorectal cancer-indications for anti-TNF-alpha agents in cancer treatment. Cell Oncol. (Dordr.) 2010, 34(4):315-326.
24. Neumark E., et al. Progression of mouse mammary tumors: MCP-1-TNFalpha cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors. Int. J. Cancer 2003, 106(6):879-886.
25. Aronica S.M., et al. Macrophage inflammatory protein-1alpha and interferon-inducible protein 10 inhibit synergistically induced growth factor stimulation of MAP kinase activity and suppress phosphorylation of eukaryotic initiation factor 4E and 4E binding protein 1. Blood 1997, 89(10):3582-3595.
26. Schroder A.K., et al. Polymorphonuclear leucocytes selectively produce anti-inflammatory interleukin-1 receptor antagonist and chemokines, but fail to produce pro-inflammatory mediators. Immunology 2006, 119(3):317-327.
27. Lawson J.A., et al. The hepatic inflammatory response after acetaminophen overdose: role of neutrophils. Toxicol. Sci. 2000, 54(2):509-516.
28. Nagasawa T., et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996, 382(6592):635-638.
29. Gholamhossein H., Mohammad Ebrahim R., Mohammad Kazemi A., Ali S., Mehdi M., Ali M., Alan J.D. Expression of regulated oncogen-alpha by primary hepatocytes following isolation and heat shock stimulation. Iran. J. Biotechnol. 2009, 7(1):1120-1125.
30. Michalopoulos G.K., DeFrances M.C. Liver regeneration. Science 1997, 276(5309):60-66.